News

As of the expiration of the tender offer, a total of approximately 25,491,221 shares of Ventana common stock were tendered and not withdrawn, representing approximately 70.5% of Ventana’s

The Phase I trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma. Rajesh Shrotriya,

The deal is in sync with Belupo’s strategy to strengthen its position in the Balkans and pave the way for creating new markets. The company manufactures 95 pharmaceuticals

Hema Diagnostic Systems (HDS) will incorporate the ABMC syphilis test strip into HDS’s Rapid 1-2-3 Hema Express delivery system. The HDS Express generates results in approximately 15-20 minutes,

US Renal Care plans to expand Eumana’s unique service offering of home dialysis in other markets where it already operates. By adding these services in other markets, US

Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional payments including development and commercial milestones, and royalties on any

The Phase III trial has been designed as a global, randomized, multi-center open label trial to prospectively evaluate the safety and efficacy of Karenitecin compared to the chemotherapy

Michael Butler, Life Spine’s president, CEO and founder, said: “We now have an entire family of cervical options to address a wide variety of patient and surgeon needs,

Funds raised through this financing will allow BioVascular to complete ongoing clinical trials of its two compounds, saratin and BVI-007. The company has raised a total of $18.87